Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Darrow, Jonathan J.
37  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

Prioritizing Early Disease Intervention:

Caicedo, H. H ; Darrow, Jonathan J ; Caicedo, Julio C.
https://doi.org/10.1007/s43441-023-00569-3.  , 2023
Link: https://hdl.handle.net/1..
 
?
2

Repositioning Generic Drugs: Empirical Findings and Policy ..:

Liddicoat, Johnathon ; Liddell, Kathleen ; Darrow, Jonathan...
Liddicoat , J , Liddell , K , Darrow , J , Aboy , M , Jordan , M , Crespo , C & Minssen , T 2022 , ' Repositioning Generic Drugs: Empirical Findings and Policy Implications ' , IIC- INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COMPETITION LAW , vol. 53 , no. 8 , pp. 1287-1322 . https://doi.org/10.1007/s40319-022-01241-3.  , 2022
Link: https://kclpure.kcl.ac.u..
 
?
3

Experts' Views on FDA Regulatory Standards for Drug and Hig..:

Dhruva, Sanket S ; Darrow, Jonathan J ; Kesselheim, Aaron S.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708961/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
4

Frequency of Approval and Marketing of Biosimilars With a S..:

Egilman, Alexander C ; Van de Wiele, Victor L ; Rome, Benjamin N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706396/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
5

Incremental benefits of novel pharmaceuticals in the UK: a ..:

Polak, Tobias B ; Cucchi, David GJ ; Darrow, Jonathan J.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996039/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
6

Incremental benefits of novel pharmaceuticals in the UK:A c..:

Polak, Tobias B ; Cucchi, David G.J ; Darrow, Jonathan J.
Polak , T B , Cucchi , D G J , Darrow , J J & Versteegh , M M 2022 , ' Incremental benefits of novel pharmaceuticals in the UK : A cross-sectional analysis of NICE technology appraisals from 2010 to 2020 ' , BMJ Open , vol. 12 , no. 4 , e058279 . https://doi.org/10.1136/bmjopen-2021-058279.  , 2022
Link: https://pure.eur.nl/en/p..
 
?
7

Fulfillment of Postmarket Commitments and Requirements for ..:

Brown, Beatrice L ; Mitra-Majumdar, Mayookha ; Darrow, Jonathan J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531062/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Experts' Views on FDA Regulatory Standards for Drug and Hig..:

Dhruva, Sanket S ; Darrow, Jonathan J ; Kesselheim, Aaron S.
qt8vx1s013.  , 2022
Link: https://escholarship.org..
 
?
9

Generating Evidence from Expanded Access Use of Rare Diseas..:

Polak, Tobias B ; Cucchi, David G. J ; van Rosmalen, Joost..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168458/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Safeguarding evidence-based decision making in the FDA for ..:

Angelis, Aris ; Darrow, Jonathan
https://researchonline.lshtm.ac.uk/id/eprint/4660158/1/Title_Manuscript_Clean_Unmarked_Accepted.pdf.  , 2021
Link: https://researchonline.l..
 
?
11

The timing of 30‐month stay expirations and generic entry: ..:

Kannappan, Sunand ; Darrow, Jonathan J ; Kesselheim, Aaron S.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504843/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
12

Incentivizing Antibiotic Development: Why Isn't the Generat..:

Darrow, Jonathan J ; Kesselheim, Aaron S
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986775/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
13

Designing development programs for non-traditional antibact..:

Rex, John H ; Fernandez Lynch, Holly ; Cohen, I. Glenn..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668399/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
14

The FDA's Expedited Programs and Clinical Development Times..:

Hwang, Thomas J ; Darrow, Jonathan J ; Kesselheim, Aaron S
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820715/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
15

Trends in utilization of FDA expedited drug development and..:

Kesselheim, Aaron S ; Wang, Bo ; Franklin, Jessica M.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580726/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
1-15